Lori Leslie, MD, Discusses CAR T-cell therapy and DLBCL
Lori Leslie, MD, of the John Theurer Cancer Center, sat down to discuss the relationship between chimeric antigen receptor (CAR) T-cell therapy and diffuse large B cell lymphoma (DLBCL) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.
Transcription:
So, I think in DLBCL right now CAR T-cell (therapy) is very exciting (and) really has revolutionized how we treat patients with relapsed/refractory disease. There’s some very interesting CAR T information being presented at ASH.
I’m interested in the mechanisms of resistance. So even though CAR T is an effective therapy, long-term remissions overall are about 40%. So is it the loss of CD19, different CD19 epitopes, that leads to (patients’) progressions or lack of responses (that) is really changing development of CAR T(-cell therapy).
How do we combine therapies? How do we create different targets? Maybe dual specific targets for CAR T(-cell therapy) to help increase the overall efficacy of long-term (complete responses) and potentially cure patients.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
